Cargando…

Infectious Risks and Complications in Adult Leukemic Patients Receiving Blinatumomab

BACKGROUND: Blinatumomab is an anti-CD19 immunotherapy approved for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) with significantly increased survival rate. While blinatumomab showed lower rates of infection, neutropenia and mucosal barrier injury versus chemotherapy, its infection...

Descripción completa

Detalles Bibliográficos
Autores principales:	So, Wonhee, Pandya, Shuchi, Quilitz, Rod, Shah, Bijal, Greene, John N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937972/ https://www.ncbi.nlm.nih.gov/pubmed/29755706 http://dx.doi.org/10.4084/MJHID.2018.029

Ejemplares similares

703. Mechanisms of High-Level Ceftolozane/Tazobactam (CT) Resistance Against Pseudomonas aeruginosa and Synergy Between CT and Tobramycin (TOB)
por: So, Wonhee, et al.
Publicado: (2018)

2690. Infectious Complications in Adult Leukemic Patients with Prolonged Neutropenia Undergoing Induction Chemotherapy
por: Sabapathy, Vidhya, et al.
Publicado: (2019)

742. Breakthrough Invasive Fungal Infections with Isavuconazonium Sulfate versus Voriconazole as Primary Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia (AML) who Received Induction Chemotherapy
por: Singam, Hareesh v, et al.
Publicado: (2020)

755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults
por: Al-Bahou, Amanda, et al.
Publicado: (2021)

Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk
por: Wo, Stephanie, et al.
Publicado: (2022)

Blinatumomab-associated vasculitis
por: Liau, MeiQi May, et al.
Publicado: (2017)

Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature
por: Schober, Sarah, et al.
Publicado: (2020)

Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies
por: Clements, John David, et al.
Publicado: (2019)

1301. Breakthrough Invasive Fungal Infections based on CYP2C19 Levels in Patients Who were on Voriconazole as Primary Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) undergoing Induction Chemotherapy
por: Singam, Hareesh v, et al.
Publicado: (2020)

Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia who have been treated with blinatumomab
por: Mikhailova, Ekaterina, et al.
Publicado: (2020)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
por: Lee, Kum Ja, et al.
Publicado: (2016)

Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab
por: Hladnik,1, Lindsay, et al.
Publicado: (2016)

Blinatumomab in Ph+ B-ALL: present and perspectives
por: Papayannidis, Cristina, et al.
Publicado: (2017)

Recent advances on blinatumomab for acute lymphoblastic leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Cytokine Release Syndrome Following Blinatumomab Therapy
por: Ojemolon, Pius E, et al.
Publicado: (2022)

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
por: Gökbuget, N, et al.
Publicado: (2016)

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment
por: Pourhassan, Hoda, et al.
Publicado: (2023)

A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test
por: Yamamoto, Yasuto, et al.
Publicado: (2022)

Blinatumomab as bridging therapy in paediatric B‐cell acute lymphoblastic leukaemia complicated by invasive fungal disease
por: Yeoh, Daniel K., et al.
Publicado: (2022)

Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
por: Wei, Andrew H., et al.
Publicado: (2021)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

Necrotizing Cellulitis and Myositis in a Neutropenic Leukemic Patient
por: Alok, Akankcha, et al.
Publicado: (2021)

Comment on 'Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia'
por: Tong, W H
Publicado: (2016)

Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
por: Niyongere, Sandrine, et al.
Publicado: (2020)

Rosacea Granulomatosis in a Neutropenic Leukemic Patient
por: Lee, Woo Joo, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma
por: Hijazi, Youssef, et al.
Publicado: (2018)

Blinatumomab-induced T cell activation at single cell transcriptome resolution
por: Huo, Yi, et al.
Publicado: (2021)

Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia
por: Kiyoi, Hitoshi, et al.
Publicado: (2020)

Infectious Complications of DiGeorge Syndrome in the Setting of Malignancy
por: Hare, Heather, et al.
Publicado: (2022)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
por: Le Jeune, Caroline, et al.
Publicado: (2016)

COVID-19 infection during blinatumomab therapy: Is safety a dilemma?
por: Barahona-Correa, Julián E, et al.
Publicado: (2023)

Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells
por: Wu, Shang-Ju, et al.
Publicado: (2023)

Treatment of Relapsed B/T-cell Mixed Phenotype Acute Leukemia With Blinatumomab
por: Abdo, Yasmeen, et al.
Publicado: (2023)

Multidisciplinary approach in diagnosis and treatment of COVID-19-associated mucormycosis: a description of current reports
por: Gogineni, Hyma, et al.
Publicado: (2022)

Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Stein, Anthony, et al.
Publicado: (2018)

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL
por: Locatelli, Franco, et al.
Publicado: (2022)

Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
por: Franquiz, Miguel J, et al.
Publicado: (2020)

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Song, Jinlin, et al.
Publicado: (2019)

Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
por: Portell, Craig A, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_flaf02rebqkdvdhh4qoghsp2vg